share_log

Canaccord Genuity Maintains Buy on CervoMed, Lowers Price Target to $12

Benzinga ·  Dec 12 01:24  · Ratings

Canaccord Genuity analyst Sumant Kulkarni maintains CervoMed (NASDAQ:CRVO) with a Buy and lowers the price target from $65 to $12.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment